JP2016518379A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2016518379A5 JP2016518379A5 JP2016509434A JP2016509434A JP2016518379A5 JP 2016518379 A5 JP2016518379 A5 JP 2016518379A5 JP 2016509434 A JP2016509434 A JP 2016509434A JP 2016509434 A JP2016509434 A JP 2016509434A JP 2016518379 A5 JP2016518379 A5 JP 2016518379A5
- Authority
- JP
- Japan
- Prior art keywords
- agent
- composition according
- sulfolobus
- variant
- fold protein
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000000203 mixture Substances 0.000 claims 11
- 108090000623 proteins and genes Proteins 0.000 claims 9
- 102000004169 proteins and genes Human genes 0.000 claims 9
- 230000027455 binding Effects 0.000 claims 4
- 239000003795 chemical substances by application Substances 0.000 claims 4
- 239000000499 gel Substances 0.000 claims 3
- 230000000699 topical Effects 0.000 claims 3
- 102000004127 Cytokines Human genes 0.000 claims 2
- 108090000695 Cytokines Proteins 0.000 claims 2
- 102000015696 Interleukins Human genes 0.000 claims 2
- 108010063738 Interleukins Proteins 0.000 claims 2
- 229940047122 Interleukins Drugs 0.000 claims 2
- 210000003491 Skin Anatomy 0.000 claims 2
- 241000205095 Sulfolobus shibatae Species 0.000 claims 2
- 241000205091 Sulfolobus solfataricus Species 0.000 claims 2
- 241000160715 Sulfolobus tokodaii Species 0.000 claims 2
- 239000003446 ligand Substances 0.000 claims 2
- 230000000813 microbial Effects 0.000 claims 2
- 101710030448 sso7a1 Proteins 0.000 claims 2
- 101710028438 sso7d Proteins 0.000 claims 2
- 208000005623 Carcinogenesis Diseases 0.000 claims 1
- 101700079752 DBP7 Proteins 0.000 claims 1
- 208000009745 Eye Disease Diseases 0.000 claims 1
- 206010062080 Pigmentation disease Diseases 0.000 claims 1
- 101710028437 Saci_0362 Proteins 0.000 claims 1
- 210000002966 Serum Anatomy 0.000 claims 1
- 101710030443 SiH_0663 Proteins 0.000 claims 1
- 208000006641 Skin Disease Diseases 0.000 claims 1
- 241000205098 Sulfolobus acidocaldarius Species 0.000 claims 1
- 239000004480 active ingredient Substances 0.000 claims 1
- 239000000443 aerosol Substances 0.000 claims 1
- 239000000058 anti acne agent Substances 0.000 claims 1
- 239000003242 anti bacterial agent Substances 0.000 claims 1
- 239000002260 anti-inflammatory agent Substances 0.000 claims 1
- 229940121363 anti-inflammatory agents Drugs 0.000 claims 1
- 102000004965 antibodies Human genes 0.000 claims 1
- 108090001123 antibodies Proteins 0.000 claims 1
- 239000003429 antifungal agent Substances 0.000 claims 1
- 239000000427 antigen Substances 0.000 claims 1
- 102000038129 antigens Human genes 0.000 claims 1
- 108091007172 antigens Proteins 0.000 claims 1
- 239000003096 antiparasitic agent Substances 0.000 claims 1
- 239000003908 antipruritic agent Substances 0.000 claims 1
- 239000003443 antiviral agent Substances 0.000 claims 1
- 239000000969 carrier Substances 0.000 claims 1
- 230000001413 cellular Effects 0.000 claims 1
- 239000006071 cream Substances 0.000 claims 1
- 230000004069 differentiation Effects 0.000 claims 1
- 201000010099 disease Diseases 0.000 claims 1
- 239000006185 dispersion Substances 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 229940079593 drugs Drugs 0.000 claims 1
- 239000000839 emulsion Substances 0.000 claims 1
- 239000002158 endotoxin Substances 0.000 claims 1
- 239000006260 foam Substances 0.000 claims 1
- 239000003193 general anesthetic agent Substances 0.000 claims 1
- 239000003410 keratolytic agent Substances 0.000 claims 1
- 239000006210 lotion Substances 0.000 claims 1
- 239000004530 micro-emulsion Substances 0.000 claims 1
- 108020004707 nucleic acids Proteins 0.000 claims 1
- 150000007523 nucleic acids Chemical class 0.000 claims 1
- 230000019612 pigmentation Effects 0.000 claims 1
- 108090000765 processed proteins & peptides Proteins 0.000 claims 1
- 102000004196 processed proteins & peptides Human genes 0.000 claims 1
- 230000035755 proliferation Effects 0.000 claims 1
- 239000002516 radical scavenger Substances 0.000 claims 1
- 102000005962 receptors Human genes 0.000 claims 1
- 108020003175 receptors Proteins 0.000 claims 1
- 230000001105 regulatory Effects 0.000 claims 1
- 239000000243 solution Substances 0.000 claims 1
- 239000007921 spray Substances 0.000 claims 1
Claims (10)
- 野生型OBフォールドタンパク質のその天然リガンドへの結合界面に5から32個の変異残基を有する野生型OBフォールドタンパク質の変異体を含む、局所用組成物。
- 前記野生型OBフォールドタンパク質が、スルホロブス・アシドカルダリウス(Sulfolobus acidocaldarius)由来のSac7dまたはSac7e、スルホロブス・ソルファタリカス(Sulfolobus solfataricus)由来のSso7d、スルホロブス・トコダイイ(Sulfolobus tokodaii)由来のDBP 7、スルホロブス・シバタエ(Sulfolobus shibatae)由来のSsh7b、スルホロブス・シバタエ由来のSsh7a、およびスルホロブス・ソルファタリカス由来のp7ssから選択されることを特徴とする、請求項1記載の組成物。
- 10 mg/mlから600 mg/mlの前記変異体を含有することを特徴とする、請求項1および2のいずれか一項記載の組成物。
- 前記変異体が、抗原、抗体、細胞タンパク質、循環タンパク質、ペプチド、薬剤の活性成分、核酸、および特にインターロイキン、サイトカイン、サイトカインまたはインターロイキンの受容体、癌遺伝子によりコードされるタンパク質、微生物の表面タンパク質、ならびに微生物リポ多糖から選択される対象の標的に結合することを特徴とする、請求項1から3のいずれか一項記載の組成物。
- 皮膚に適用することが意図されていることを特徴とする、請求項1から4のいずれか一項記載の組成物。
- 眼レベルで適用することが意図されていることを特徴とする、請求項1から4のいずれか一項記載の組成物。
- 水性、油性もしくは水性-アルコール性溶液、エマルジョン、マイクロエマルジョン、水性ゲル、無水ゲル、美容液、小胞分散系、ローション、ゲル、クリーム、泡、エアロゾルまたはスプレーの形態にあることを特徴とする、請求項1から6のいずれか一項記載の組成物。
- 抗菌剤、抗寄生虫剤、抗真菌剤、抗炎症剤、鎮痒剤、麻酔剤、抗ウイルス剤、角質溶解剤、フリーラジカルスカベンジャー、抗脂漏剤、フケ防止剤、および抗ニキビ剤、ならびに皮膚の分化および/または増殖および/または色素沈着を調節するための作用物質から選択される少なくとも1つの作用物質も含有することを特徴とする、請求項1から7のいずれか一項記載の組成物。
- 皮膚または眼の障害または疾患の処置における使用のための、請求項1から8のいずれか一項記載の局所用組成物。
- 野生型OBフォールドタンパク質のその天然リガンドへの結合界面に5から32個の変異残基を有する野生型OBフォールドタンパク質の変異体を薬学的にまたは化粧用に許容される担体と混合する段階を含む、請求項1から9のいずれか一項記載の局所用組成物を調製するための方法。
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
FR1353662A FR3004650B1 (fr) | 2013-04-22 | 2013-04-22 | Composition topique comprenant un variant d'une protéine sauvage à pli-OB, ainsi que son procédé de préparation |
FR13/53662 | 2013-04-22 | ||
PCT/EP2014/058139 WO2014173899A1 (fr) | 2013-04-22 | 2014-04-22 | Compositions topiques comprenant des variantes de pli-ob |
Related Child Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2019022358A Division JP2019112410A (ja) | 2013-04-22 | 2019-02-12 | Obフォールド変異体を含む局所用組成物 |
Publications (2)
Publication Number | Publication Date |
---|---|
JP2016518379A JP2016518379A (ja) | 2016-06-23 |
JP2016518379A5 true JP2016518379A5 (ja) | 2017-06-15 |
Family
ID=48795734
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2016509434A Pending JP2016518379A (ja) | 2013-04-22 | 2014-04-22 | Obフォールド変異体を含む局所用組成物 |
JP2019022358A Pending JP2019112410A (ja) | 2013-04-22 | 2019-02-12 | Obフォールド変異体を含む局所用組成物 |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2019022358A Pending JP2019112410A (ja) | 2013-04-22 | 2019-02-12 | Obフォールド変異体を含む局所用組成物 |
Country Status (7)
Country | Link |
---|---|
US (2) | US10548945B2 (ja) |
EP (1) | EP2988766B1 (ja) |
JP (2) | JP2016518379A (ja) |
CN (2) | CN105338995B (ja) |
ES (1) | ES2637421T3 (ja) |
FR (1) | FR3004650B1 (ja) |
WO (1) | WO2014173899A1 (ja) |
Families Citing this family (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
FR3004650B1 (fr) * | 2013-04-22 | 2015-05-29 | Affilogic | Composition topique comprenant un variant d'une protéine sauvage à pli-OB, ainsi que son procédé de préparation |
FR3027521B1 (fr) | 2014-10-24 | 2016-12-16 | Affilogic | Compositions pour administration par voie orale |
EP3483180A1 (en) * | 2017-11-14 | 2019-05-15 | Affilogic | Multi specific molecules |
EP3632924A1 (en) | 2018-10-07 | 2020-04-08 | Affilogic | Binders for inhibiting formation of multimeric proteins |
US11597751B2 (en) | 2019-05-16 | 2023-03-07 | Massachusetts Institute Of Technology | Glycan-binding proteins and related compositions and methods |
EP3878858A1 (en) | 2020-03-11 | 2021-09-15 | Affilogic | Variants of sac7d and their use in cancer therapy |
EP4043481A1 (en) | 2021-02-15 | 2022-08-17 | Affilogic | Compounds and methods for extending half life of biomolecules |
EP4059949A1 (en) | 2021-03-18 | 2022-09-21 | Affilogic | Anti-factor c3 sac7d variants and their medical use for treating complement-mediated disorders |
EP4308590A1 (en) | 2021-03-18 | 2024-01-24 | Affilogic | Anti-factor c3 sac7d variants and their medical use for treating complement-mediated disorders |
CN117106745A (zh) * | 2022-06-01 | 2023-11-24 | 北京擎科生物科技股份有限公司 | 逆转录突变体及其应用 |
Family Cites Families (15)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20030228616A1 (en) * | 1999-10-29 | 2003-12-11 | Stratagene | DNA polymerase mutants with reverse transcriptase activity |
CA2653752A1 (en) * | 2006-05-26 | 2007-12-06 | Vickery Laurence Arcus | Ob fold domains |
ATE542830T1 (de) * | 2006-12-04 | 2012-02-15 | Pasteur Institut | Als gerüst verwendeter ob-fold zur entwicklung neuer spezifischer bindemittel |
EP2358746B1 (en) * | 2008-11-03 | 2020-09-16 | Molecular Partners AG | Binding proteins inhibiting the vegf-a receptor interaction |
US20110098216A1 (en) * | 2009-10-22 | 2011-04-28 | Regen Therapeutics Plc | Therapeutic uses of colostrinin |
EP2469278A1 (en) * | 2010-12-21 | 2012-06-27 | Institut Pasteur | Reagentless fluorescent biosensors from nanofitins, rational design methods to create reagentless fluorescent biosensors and methods of their use |
FR2974816A1 (fr) * | 2011-05-04 | 2012-11-09 | Centre Nat Rech Scient | Methode de generation de proteines |
FR3004650B1 (fr) * | 2013-04-22 | 2015-05-29 | Affilogic | Composition topique comprenant un variant d'une protéine sauvage à pli-OB, ainsi que son procédé de préparation |
FR3027521B1 (fr) * | 2014-10-24 | 2016-12-16 | Affilogic | Compositions pour administration par voie orale |
PL412787A1 (pl) * | 2015-06-22 | 2017-01-02 | Magdalena Król | Oparty na makrofagach celowany system dostarczania związków związanych z ferrytyną |
WO2018048941A2 (en) * | 2016-09-08 | 2018-03-15 | The Board Of Trustees Of The Leland Stanford Junior University | Use of high affinity monoclonal antibody product binders to increase the duration of action of therapeutic monoclonal antibody products in a biologic tissue |
EP3483180A1 (en) * | 2017-11-14 | 2019-05-15 | Affilogic | Multi specific molecules |
EP3632924A1 (en) * | 2018-10-07 | 2020-04-08 | Affilogic | Binders for inhibiting formation of multimeric proteins |
EP3878858A1 (en) * | 2020-03-11 | 2021-09-15 | Affilogic | Variants of sac7d and their use in cancer therapy |
EP4059949A1 (en) * | 2021-03-18 | 2022-09-21 | Affilogic | Anti-factor c3 sac7d variants and their medical use for treating complement-mediated disorders |
-
2013
- 2013-04-22 FR FR1353662A patent/FR3004650B1/fr not_active Expired - Fee Related
-
2014
- 2014-04-22 CN CN201480030115.3A patent/CN105338995B/zh active Active
- 2014-04-22 EP EP14718621.7A patent/EP2988766B1/fr active Active
- 2014-04-22 CN CN202010402321.XA patent/CN111467477A/zh active Pending
- 2014-04-22 US US14/786,287 patent/US10548945B2/en active Active
- 2014-04-22 JP JP2016509434A patent/JP2016518379A/ja active Pending
- 2014-04-22 ES ES14718621.7T patent/ES2637421T3/es active Active
- 2014-04-22 WO PCT/EP2014/058139 patent/WO2014173899A1/fr active Application Filing
-
2019
- 2019-02-12 JP JP2019022358A patent/JP2019112410A/ja active Pending
- 2019-12-24 US US16/726,305 patent/US10898542B2/en active Active
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP2016518379A5 (ja) | ||
Chaulagain et al. | Passive delivery of protein drugs through transdermal route | |
HRP20190799T1 (hr) | Imunocitokini na bazi il-15 i sushi domene il-15r alfa | |
EP4299137A3 (en) | Extracellular vesicle comprising a fusion protein having fc binding capacity | |
WO2019126762A3 (en) | Cas12a systems, methods, and compositions for targeted rna base editing | |
WO2020077276A3 (en) | Pd-1 targeted il-15/il-15ralpha fc fusion proteins and uses in combination therapies thereof | |
MX2018010824A (es) | Proteinas de union inducibles y metodos de uso. | |
JP2015530358A5 (ja) | ||
BR112015022210A2 (pt) | formulações farmacêuticas aquosas estáveis, seu uso, artigo de manufatura, métodos de redução da agregação de um anticorpo monoclonal terapêutico e método de produção de uma formulação farmacêutica. | |
CN105884888B (zh) | 一种基于金纳米粒子的人工抗体构建方法 | |
WO2019241893A3 (en) | Anti-her3 antibody and uses thereof | |
WO2017066132A3 (en) | Synthetic antibody mimic peptides | |
US20160143990A1 (en) | Topical Compositions Comprising OB-Fold Variants | |
CN105980447A (zh) | 二氧化硅囊泡的合成方法及其用途 | |
WO2007119011A9 (fr) | Proteines de fusion proteine n d'un virus de la famille des paramyxoviridae-proteine d'interet | |
HRP20161096T1 (hr) | Antigenski vežući proteini specifični za komponentu p serumskog amiloida | |
WO2019180201A3 (en) | Antagonistic pd-1, pd-l1 and lag-3 binding proteins | |
BR112019028070A2 (pt) | peptídeos e combinações de peptídeos para uso em imunoterapia contra câncer de pulmão, incluindo cpcnp, cppc e outros cânceres | |
WO2016063026A3 (en) | Selective nav protein binders | |
RU2019113989A (ru) | Лекарственное средство | |
BR112019005001A2 (pt) | proteína de ligação ao antígeno, proteína de fusão, ácido nucleico, vetor recombinante, célula hospedeira recombinante, composição farmacêutica, uso médico da proteína de ligação ao antígeno e método de inibição do crescimento tumoral | |
WO2014144768A3 (en) | Bh4 stabilized peptides and uses thereof | |
BR112022014574A2 (pt) | Proteína heterodimérica, anticorpo ativável, um ou mais ácidos nucleicos, vetor, célula hospedeira, composição farmacêutica e métodos para preparar uma proteína heterodimérica ou um anticorpo ativável e para tratar uma doença | |
WO2018020324A3 (en) | Virus-like particles with high-density coating for inducing the expression of antibodies | |
EA202190572A1 (ru) | Иммунотерапия раковых заболеваний рестриктированными по a*01 пептидами и комбинациями пептидов и относящиеся к ней способы |